" class="no-js "lang="en-US"> Philippe Halfon - Medtech Alert
Thursday, March 30, 2023

Breaking News

Nanoscope Therapeutics Announces Positive Topline Results from Phase 2b RESTORE Trial of MCO-010 for the Treatment of Retinitis Pigmentosa Glyscend Therapeutics Appoints Biotech Industry Veteran Michael Wyzga to its Board of Directors Trobix Bio Raises $3 Million from Chartered Group to Advance Precision Microbiome Oncology Therapeutics Mathai Mammen to Join FogPharma as Chairman, President and Chief Executive Officer Confo Therapeutics Enters into Collaboration Agreement with Daiichi Sankyo to Discover Novel Medicines for CNS Diseases Implantica Launches RefluxStop™ in Italy Granular Therapeutics to Accelerate Development of Next-Generation Pipeline for Treating Mast Cell Driven Diseases Xeris Biopharma Appoints Ricki Fairley to Board of Directors AskBio to Present Phase 1b Results Investigating AB-1005 as Treatment for Parkinson’s Disease New Imaging Method for Evaluating Transport of Oxygen to Blood Cells
Philippe Halfon

Philippe Halfon

About Philippe Halfon

Philippe Halfon (MD, PhD) is a serial entrepreneur. President and Co-founder of Alphabio, and Head of Internal Medecine at the European Hospital in Marseille, he has deep experience in viral diseases (especially in HCV, HBV and HIV) and liver diseases. Philippe has used his scientific and medical knowledge to lead Genoscience Pharma since its inception in 2001.

Related Story

Industry News

 Genoscience Pharma Licences GNS561

Genoscience Pharma Licenses GNS561, its PPT-1 Inhibitor, to GENFIT in Cholangiocarcinoma Indication in US/Canada and Europe

December 17 2021

Genoscience Pharma, a clinical stage biotechnology company developing unique lysosomotropic drug candidates for the treatment of […]